Navigation Links
Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
Date:11/7/2007

g the course of vascular disease potentially by increasing inflammation in the arterial wall thus leading to exacerbation of atherosclerosis, which could reduce blood supply to target limbs and organs.

"The conclusive data obtained from this well-powered and well-executed study provides a compelling argument that C. pneumoniae does not play a role in PAD that is modifiable by anti-bacterial therapy. Walking impairment in PAD patients remains a significant unmet medical need, but anti-chlamydial therapy does not appear to be the solution," Dr. Jaff said.

About ActivBiotics, Inc.

ActivBiotics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of inflammatory diseases and bacterial infections. For more information on ActivBiotics, Inc., please visit our web site http://www.activbiotics.com.

Safe Harbor Statement

This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words "may," "believes," "will", "expects," "anticipates" or the negation thereof, or similar expressions, which constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statemen
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... NEW YORK , April 1, 2015  The ... ("ASPX" or the "Company") by Teva Pharmaceutical Industries ("Teva") ... action, shareholder rights law firm.  The investigation focuses on ... law by the Board of Directors of ASPX for ... 30, 2015, the Company announced a definitive agreement for ...
(Date:4/1/2015)... April 1, 2015 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral ... been enrolled in its Glucose Clamp Study. The study ... Science Center at San Antonio ... supervision of Professor Ralph DeFronzo . ...
(Date:4/1/2015)... KONG , April 1, 2015 Jintian ... code: 2211) announced that Mr. Jin Dongtao, chairman and ... the Company, representing 2% of the existing entire issued ... at HK$2.82 per share with the total amount of ... Mr. Jin Dongtao,s shareholding will increase from 45.17% to ...
Breaking Medicine Technology:WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 2Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 3Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 4Chairman of Jintian Pharmaceutical Purchased Approximately HK$113 Million Worth of Shares Citing Confidence in Company's Development in Online and Offline MacroHealth Business 5
... BNVI ) announced today that it will release ... ended September 30, 2010 on Thursday, November 11, 2010. The ... the financial results on Thursday, November 11, 2010 at 5:00 ... by dialing (877) 317-6789 or (412) 317-6789, or can listen ...
... Eli Lilly and Company (NYSE: LLY ) ... today presented an $11.6 million check to the United ... employees and retirees and a matching gift amount from ... Central Indiana chapter and other United Way chapters, 2010 ...
Cached Medicine Technology:Lilly Surpasses United Way 2010 Campaign Goal 2
(Date:4/1/2015)... 01, 2015 This year for Oral Cancer ... Cancer Foundation for an Open House to offer complimentary oral ... to 4 p.m. An appointment is required and can be ... at 212-689-0024. In addition, Herald Square Dental and The ... entire month of April at the reduced cost of $39 ...
(Date:4/1/2015)... 01, 2015 Bird B Gone, the ... residential applications now offers a complete line of ... of bird netting products quickly, safely and efficiently. , ... of any bird netting installation. It’s important to determine ... stages of a project. This includes deciding whether to ...
(Date:4/1/2015)... After a particularly harsh winter, many roads are now littered ... damage, so Amica Insurance has tips to help ... from AAA: , , Inspect tires: Tires ... manufacturer’s recommended levels. , Inspect suspension: ... wear can be signs of bad shocks or struts. Have ...
(Date:4/1/2015)... 2015 Taking an important step forward ... for Nursing Commission for Nursing Education Accreditation (NLN CNEA) ... first NLN CNEA Board of Commissioners. Working with executive ... 15-member board will provide leadership and direction to accreditation ... decisions for nursing programs that seek accreditation from the ...
(Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
Breaking Medicine News(10 mins):Health News:Herald Square Dental Celebrates Oral Cancer Awareness Month 2Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 2Health News:Bird B Gone Now Carries Complete Bird Netting Hardware 3Health News:Prepare for potholes with 7 tips from Amica Insurance 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 2Health News:NLN Commission for Nursing Education Accreditation (NLN CNEA) Announces Inaugural Commissioners 3Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2
... May 22 Setaram Inc., a leading,manufacturer ... gas sorption and high pressure mass spectroscopy ... to announce the,appointment of Bruce Jamieson as ... recent acquisition of Hy-Energy LLC (Newark, CA), ...
... Minimally Invasive P3(TM) (Pioneer Peek-on-Peek) ... Technology Motion Preservation Device, DRIEBERGEN, ... announced the BacJac(TM),Interspinous Decompression System (IDS) will be market ... Switzerland., The BacJac system is designed to relieve ...
... HHS Secretary Mike,Leavitt today announced efforts underway at ... Centers for Medicare & Medicaid Services (CMS),that will ... the quality,of medical care., "This initiative will ... of medical products on the market," Secretary Leavitt ...
... 21, 2008 If you were sick, wouldnt you ... you" Or a treatment that prevents you from ever ... of clinical and translational science provides the bridging force ... Editor, Scott A. Waldman, MD, PhD, and Executive Editor, ...
... 22 Accenx Technologies, Inc.,announced today that ... Authorized,Subcontractor Program and is now part of ... services to the healthcare industry. From,this new ... to its already robust client roster, develop ...
... The topic of today,s,congressional subcommittee hearing on animal-disease ... Kansas and should serve several,purposes:, * Underscore ... combat the real and present threat of diseases ... economy., * Demonstrate the urgency of addressing ...
Cached Medicine News:Health News:Setaram Inc. Appoints New CEO/VP 2Health News:Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 2Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 3Health News:New Efforts to Help Improve Medical Products for Patient Safety and Quality of Medical Care 4Health News:Unlocking the promise of clinical and translational science 2Health News:Accenx Technologies Joins Sun's Authorized Subcontractor Program 2Health News:Tip Sheet: Kansas Responds to Congressional Hearing on Animal Disease Research 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: